NIDA Notes keeps you up to date on research advances in the causes, consequences, prevention, and treatment of drug abuse and addiction and HIV/AIDS.
Learn more about NIDA Notes
Reports on research of chronic cocaine abusers who may feel they are sleeping better during early abstinence revealed that the opposite may be true.
Presents evidence that among men and women with HIV, those who received early initiation of HAART therapy, those with higher CD4+ levels, achieved better immune recovery.
Presents an update on NIDA’s Southern African Initiative, a program that aims to build research capacity and infrastructure in the area of addiction, particularly drug-related HIV transmission.
Describes a new chemical tracer that binds specifically to cannabinoid receptors making it potentially useful in future research to clarify the relationship between the receptors and drug abuse.
Describes research investigating the use of a treatment that combines vouchers and cognitive behavioral therapy as compared with the use of either treatment alone for marijuana abuse.
Summarizes research on the effects of long-term regular cocaine abuse on the cardiovascular system in African Americans.
Announces the 2007 Smissman Award from the American Chemical Society to Dr. Kenner Rice, NIDA, for significant contributions to fundamental knowledge in medicinal chemistry.
Describes a new research finding indicating that the antidepressant sertraline (Zoloft), prescribed to relieve depression during the methamphetamine withdrawal process, may make quitting harder.
Discusses the role of epigenetics, the study of cellular mechanisms that control gene expression and its impacts on health and behavior, in addiction research.
Describes a study investigating the use of the antidepressant bupropion as a potential therapy for methamphetamine addiction.
Testing a Prospective Medication To Help People Avoid Relapse
The Rise and Fall of the Cocaine High
Electronic Tools for Use in the Continuum of Care for Patients With Addiction
Researchers Speak: Dr. Thomas Kosten on Anti-Drug Vaccines